Bluetooth Low Energy Market Set to Triple by 2023, Reaching 1.6 Billion Device Shipments
Bluetooth Low Energy (BLE) devices are forecasted to reach over 1.6 billion annual shipments by 2023 according to ABI Research, a market-foresight advisory firm providing strategic guidance on the most compelling transformative technologies. Increasing opportunities in smart home, beacons and asset tracking, emerging IoT applications, alongside growth in existing key markets and the emergence of audio over BLE will enable the technology to achieve a CAGR of 27% between 2018 and 2023, tripling in size.
“Bluetooth Low Energy has witnessed tremendous growth since its introduction in 2010 because continued technical enhancements have ensured that the technology can take advantage of opportunities across an ever-increasing number of verticals and use cases,” said Andrew Zignani, Senior Analyst at ABI Research. “BLE’s ubiquitous support in mobile devices, combined with its ability to support mesh networking, beacon functionality, and most recently, centimeter level location accuracy with the introduction of Bluetooth 5.1 and radio direction finding (RDF), is enabling BLE to be increasingly leveraged within smart consumer devices, larger scale home and commercial building automation environments, and RTLS deployments with more stringent accuracy requirements,” says Zignani.
In addition to these recent enhancements, from 2020 onward, Bluetooth is anticipated to enable high-quality audio streaming over BLE, providing a boost for the existing headset market and the emerging True Wireless audio device market. “Late last year and more recently during CES 2019, Dialog Semiconductor demonstrated an audio over BLE proof of concept utilizing their SmartBond SoCs. From 2020, we expect the Bluetooth audio market to take advantage of upcoming enhancements to better support truly cable-free earbud experiences while enhancing the battery life and user experience, though it may take some time for the standardization process to translate to wider mobile and ecosystem support,” Zignani explained. Meanwhile, Bluetooth Low Energy chipset providers continue to innovate to provide further improvements in power consumption, further extending battery life and enabling support for battery-free devices via energy harvesting.
“Together, Bluetooth’s existing and upcoming enhancements will provide an enormous opportunity for the likes of Nordic Semiconductor, Dialog Semiconductor, Silicon Labs, Texas Instruments, Microchip, Cypress, STMicroelectronics, Atmosic, NXP, CEVA, and Imagination, among several other IC and IP providers who are heavily invested in the Bluetooth and BLE ecosystem,” Zignani concluded.
These findings are from ABI Research’s Wireless Connectivity Technology Segmentation & Addressable Markets market data report. This report is part of the company’s Wi-Fi, Bluetooth and Wireless Connectivity research service, which includes research, data, and Executive Foresights. Market Data spreadsheets are composed of deep data, market share analysis, and highly segmented, service-specific forecasts to provide detailed insight where opportunities lie.
About ABI Research
ABI Research provides strategic guidance
for visionaries needing market foresight on the most compelling
transformative technologies, which reshape workforces, identify holes in
a market, create new business models and drive new revenue streams.
ABI’s own research visionaries take stances early on those technologies,
publishing groundbreaking studies often years ahead of other technology
advisory firms. ABI analysts deliver their conclusions and
recommendations in easily and quickly absorbed formats to ensure proper
context. Our analysts strategically guide visionaries to take action now
and inspire their business to realize a bigger picture. For more
information about subscribing to ABI’s Research Services as well as
Industrial and Custom Solutions, visionaries can contact us at
+1.516.624.2500 in the Americas, +44.203.326.0140 in Europe,
+65.6592.0290 in Asia-Pacific or visit www.abiresearch.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005283/en/
Contact information
Global
Deborah Petrara
Tel: +1.516.624.2558
pr@abiresearch.com
Christopher Leary
Tel: +1.516.624.2544
pr@abiresearch.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RSA and Swissbit Announce New Phishing-Resistant Authentication Solution for Security-First Industries1.10.2024 12:00:00 EEST | Press release
RSA, the security-first identity leader and Swissbit, a long-standing leading expert and manufacturer of storage, security, and embedded IoT solutions, announced a new, next-generation hardware authenticator series today designed to protect highly regulated industries. The RSA iShield Key 2 series, powered by Swissbit, will provide financial services, energy, healthcare, and other highly regulated organizations with the highest-level of phishing-resistant, passwordless authentication needed to simplify credential management and drive toward Zero Architecture (ZTA). Optimized for the RSA cloud identity and access management (IAM) platform, RSA® ID Plus, the RSA iShield Key 2 series offers premiere security and unparalleled flexibility. The RSA iShield Key 2 series is available for order now and will ship Q4 2024. “The worst attacks demand the best defenses. That’s why security-first leaders have trusted RSA for decades to defend them from the most damaging cyberattacks. By working with
TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal1.10.2024 11:46:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech focused on using its proprietary GMP compliant technology platform, C-Stem™, to develop life-saving cell therapies, today published an article in Neurotherapeutics, demonstrating the first successful bioproduction of a Parkinson’s Disease cell therapy in a scalable bioreactor, leading to full behavioral recovery 16 weeks after transplantation using a cryopreserved 3D microtissue format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009598667/en/ TreeFrog Therapeutics 10L bioreactor for cell therapy (Photo credits: TreeFrog Therapeutics) The potential of cell therapy for Parkinson’s Disease is well documented – dating back to pioneering studies in the 1980s using fetal cell transplants – and scientific progress over the last decades provides great hope for the future. The emergence of induced pluripotent cells (iPSCs) opened new pathways and solved one of the first ma
Datalec Precision Installations Appoints Peter Cole as Executive Vice President for APAC Region1.10.2024 11:35:00 EEST | Press release
Datalec Precision Installations (DPI), a provider of world-class data centre design, supply, build, and managed services delivering seamless and integrated end-to-end solutions for data centre operators, today announced the appointment of Peter Cole as Executive Vice President for the Asia-Pacific (APAC) region. Based in Singapore, Cole will spearhead DPI's expansion and strategic growth initiatives across APAC's dynamic data centre market, expected to nearly double to $150.59 billion by 2029. Bringing over four decades of experience in the electrotechnical and digital industry, Cole brings a wealth of expertise to his new role. He will oversee all aspects of DPI's APAC data centre business, including strategic planning, operations, and business development. "Peter's extensive experience and deep understanding of the APAC market make him the ideal leader to drive our growth in this critical region," said Danny Keeper, Group Director of DPI. "His proven track record in delivering large-
Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells1.10.2024 11:30:00 EEST | Press release
AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a substance with a new and unique mechanism of action (first-in-class) is being investigated. The drug candidate is being studied in patients with solid tumors and lymphomas. This development program builds on AOP Health’s proven success in delivering cancer stem cell targeting agents that address patients’ unmet medical needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241001468319/en/ AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart) Focus on a promising target The new compound, AOP208, targets and blocks a protein on the surface of the cancer stem cell, the serotonin receptor 1B, which may prove to be critical to treat the root cause of the disease. The compound is given orally and was designed and initially
Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study1.10.2024 10:15:00 EEST | Press release
Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) in patients with mild-to-moderate ulcerative colitis (M2M UC). These results have been published in the Journal of Clinical Medicine.1 UC is a chronic, inflammatory bowel condition which can cause recurring bloody diarrhoea, stomach pain and extreme tiredness.4 Of those living with UC, over 85% have mild-to-moderate disease.5,6,7 Usually 5-ASA compounds are the first-line therapy for people with M2M UC, followed by a stepwise treatment approach in case of non-response or intolerance. There is currently limited guidance on timely escalation and de-escalation of therapies. OPTIMISE was the first major study to investigate whether a T2T approach based on monitoring of non-invasive parameters, such as clinical symptoms and FC, can provide a significantly higher benefit for patients with M2M U
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom